Age, comorbidity, treatment decision and prognosis in lung cancer

Blanco, José Antonio Gullón; Toste, Isabel Suárez; Álvarez, Ramón Fernández; Cuadrado, Gemma Rubinos; Gonzálvez, Agustín Medina; Martín, Isidro Jesús González

doi:10.1093/ageing/afn226

Cited by 60 publications

(34 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancers (LC) are the leading cause of deaths from cancer (1)(2)(3)(4). FOXP3 + Tregs are thought to facilitate tumor growth and metastases by inhibition of antitumor immunity (5)(6)(7)(8), and accumulation of Tregs within cancers usually corresponds with poor outcomes (4,6,9), although exceptions are known (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Human lung tumor FOXP+ Tregs upregulate four “Treg-locking” transcription factors

Akimova¹,

Zhang²,

Negorev³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Human lung tumor FOXP+ Tregs upregulate four “Treg-locking” transcription factors

Akimova¹,

Zhang²,

Negorev³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

“…Other studies also showed an increase of prevalence and severity of comorbidity among elderly cancer patients using different indexes. [ 13–21 ] The severity of comorbidity scores may be related to the number of comorbidities in the elderly: 44.7% of patients >80 years had >3 comorbidities [18] …”

Section: Resultsmentioning

confidence: 99%

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?

et al. 2016

View full text Add to dashboard Cite

Background:The aim of this article is to assess the influence of comorbidities among elderly patients (at least 70 year old) undergoing surgery for early stage nonsmall cell lung cancer (NSCLC) and to explore the tolerability and efficacy of surgery in relation to stereotactic body radiotherapy (SBRT) in this patient population.Methods:A review of the literature on the prevalence of comorbidities among elderly patients with early stage NSCLC, and the impact of comorbidity factors on survival following surgery was conducted. Survival rates and the incidence of complications following SBRT for this patient population were also identified.Results:Comorbidities in elderly patients with early stage NSCLC may preclude surgery or lead to poor survival following surgery. However, chronological age alone should not be used as a deciding factor to deny curative treatment in elderly, but fit patients. Stereotactic body radiotherapy is well tolerated by elderly lung cancer patients and may result in survival rates similar to that following surgery.Conclusion:SBRT should be the treatment of choice for early stage NSCLC in elderly patients with multiple comorbidities that preclude surgery. The roles of surgery and SBRT for elderly, -fit patients with early stage NSCLC needs to be further defined in future prospective trials.

show abstract

“…Whether that is idiosyncratic to the UK healthcare system is uncertain, but ageism treatment bias has been reiterated in patients with advanced nonsmall cell lung cancer (NSCLC) (stages III and IV). 2 Whether that bias is justifi ed remains a question, but age and life expectancy are critical factors in treatment deci sions for patients with lung cancer.…”

Section: The Elderly Are Differentmentioning

confidence: 99%

The Elderly Are Different

Johnson

2011

Chest

View full text Add to dashboard Cite

Age, comorbidity, treatment decision and prognosis in lung cancer

Cited by 60 publications

References 18 publications

Human lung tumor FOXP+ Tregs upregulate four “Treg-locking” transcription factors

Human lung tumor FOXP+ Tregs upregulate four “Treg-locking” transcription factors

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?

The Elderly Are Different

Contact Info

Product

Resources

About